Biomunex Pharmaceuticals signs strategic license and co-development agreement with Onward Therapeutics for proprietary bispecific antibody program
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
• No currently marketed drugs are able to stop the progression of epilepsy, those available only help manage seizures
• More than 30% of patients do not respond adequately to those drugs carrying risks of structural damage to the brain and nervous system, comorbidities and increased mortality
• Accure Tx’s candidate ACT-03 demonstrates in animal models anti-epileptogenic activity while protecting against cognitive decline
Tollys appoints Philippe Goupit as chairman of the board
Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer
Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists
Amolyt Pharma obtient la désignation de médicament orphelin de la FDA pour l’AZP-3601 pour le traitement potentiel de l’hypoparathyroïdie
Advent France Biotechnology crée Gamut Therapeutics et finance son amorçage
Amolyt Pharma lance une collaboration de recherche avec PeptiDream
